156 related articles for article (PubMed ID: 31686902)
1. Population pharmacokinetic modeling to facilitate dose selection of tapentadol in the pediatric population.
Watson E; Khandelwal A; Freijer J; van den Anker J; Lefeber C; Eerdekens M
J Pain Res; 2019; 12():2835-2850. PubMed ID: 31686902
[TBL] [Abstract][Full Text] [Related]
2. Multiple Dose Pharmacokinetics of Tapentadol Oral Solution for the Treatment of Moderate to Severe Acute Pain in Children Aged 2 to <7 Years.
Jończyk R; Beuter C; Bulawa B; Buller S; Eibl C; Elling C; Gautrois M; Rengelshausen J; Schmidt C; Thömmes G; Khalil F
J Pain Res; 2022; 15():3103-3114. PubMed ID: 36203787
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics of Tapentadol in Children from Birth to <18 Years Old.
Khalil F; Choi SL; Watson E; Tzschentke TM; Lefeber C; Eerdekens M; Freijer J
J Pain Res; 2020; 13():3107-3123. PubMed ID: 33262645
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain.
Xu XS; Smit JW; Lin R; Stuyckens K; Terlinden R; Nandy P
Clin Pharmacokinet; 2010 Oct; 49(10):671-82. PubMed ID: 20818833
[TBL] [Abstract][Full Text] [Related]
5. Tapentadol for the Treatment of Moderate-to-Severe Acute Pain in Children Under the Age of Two Years.
Eissa A; Tarau E; Beuter C; Radic T; Watson E; Sohns M; Lefeber C; Hammer GB
J Pain Res; 2021; 14():229-248. PubMed ID: 33542653
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of multiple doses of tapentadol oral solution in the treatment of moderate to severe acute pain in children aged 2 to <18 years - a randomized, double-blind, placebo-controlled trial.
Beuter C; Volkers G; Radic T; Goldberg J; van den Anker J
J Pain Res; 2019; 12():3099-3112. PubMed ID: 32009813
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, safety, and efficacy of tapentadol oral solution for treating moderate to severe pain in pediatric patients.
Muse D; Tarau E; Lefeber C; Sohns M; Brett M; Goldberg J; Rosenburg R
J Pain Res; 2019; 12():1777-1790. PubMed ID: 31213888
[No Abstract] [Full Text] [Related]
8. First evaluation of tapentadol oral solution for the treatment of moderate to severe acute pain in children aged 6 to <18.
Finkel JC; Goldberg J; Rosenburg R; Ariyawansa J; Sun T; Ochs-Ross R; Zannikos P; Zhang L; Etropolski M
J Pain Res; 2019; 12():1925-1936. PubMed ID: 31303784
[TBL] [Abstract][Full Text] [Related]
9. Quantifying the Exposure of Tapentadol Extended Release in Japanese Patients with Cancer Pain and Bridging Tapentadol Pharmacokinetics Across Populations Using a Modeling Approach.
Zhang L; Yan X; Nobe S; Zannikos P; Etropolski M; Nandy P
Clin Drug Investig; 2017 Mar; 37(3):273-283. PubMed ID: 27853999
[TBL] [Abstract][Full Text] [Related]
10. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain.
Biondi D; Xiang J; Benson C; Etropolski M; Moskovitz B; Rauschkolb C
Pain Physician; 2013; 16(3):E237-46. PubMed ID: 23703422
[TBL] [Abstract][Full Text] [Related]
11. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
Fabre MA; Fuseau E; Ficheux H
J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetic Modeling of Tapentadol Extended Release (ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain.
Huntjens DR; Liefaard LC; Nandy P; Drenth HJ; Vermeulen A
Clin Drug Investig; 2016 Mar; 36(3):213-23. PubMed ID: 26798023
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder.
Lobo ED; Quinlan T; Prakash A
Clin Pharmacokinet; 2014 Aug; 53(8):731-40. PubMed ID: 24989060
[TBL] [Abstract][Full Text] [Related]
14. Hydromorphone population pharmacokinetics in pediatric surgical patients.
Balyan R; Dong M; Pilipenko V; Geisler K; Vinks AA; Chidambaran V
Paediatr Anaesth; 2020 Oct; 30(10):1091-1101. PubMed ID: 32702184
[TBL] [Abstract][Full Text] [Related]
15. Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations.
Toublanc N; Sargentini-Maier ML; Lacroix B; Jacqmin P; Stockis A
Clin Pharmacokinet; 2008; 47(5):333-41. PubMed ID: 18399714
[TBL] [Abstract][Full Text] [Related]
16. Tapentadol immediate-release for acute postbunionectomy pain: a phase 3, randomized, double-blind, placebo-controlled, parallel-group study in Taiwan.
Chen YJ; Chiang CC; Huang PJ; Huang J; Karcher K; Li H
Curr Med Res Opin; 2015 Nov; 31(11):2001-9. PubMed ID: 26293513
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations.
Göhler K; Brett M; Smit JW; Rengelshausen J; Terlinden R
Int J Clin Pharmacol Ther; 2013 Apr; 51(4):338-48. PubMed ID: 23357834
[TBL] [Abstract][Full Text] [Related]
18. Dose conversion between tapentadol immediate and extended release for low back pain.
Etropolski MS; Okamoto A; Shapiro DY; Rauschkolb C
Pain Physician; 2010; 13(1):61-70. PubMed ID: 20119464
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery .
Stegmann JU; Weber H; Steup A; Okamoto A; Upmalis D; Daniels S
Curr Med Res Opin; 2008 Nov; 24(11):3185-96. PubMed ID: 18851776
[TBL] [Abstract][Full Text] [Related]
20. Modeling and Simulation Analysis of Aprepitant Pharmacokinetics in Pediatric Patients With Postoperative or Chemotherapy-Induced Nausea and Vomiting.
Chain A; Wrishko R; Vasilinin G; Mouksassi S
J Pediatr Pharmacol Ther; 2020; 25(6):528-539. PubMed ID: 32839657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
